Martin Turcotte

Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Journal: Cancer research

Published: March 15, 2017

Targeting A2 adenosine receptors in cancer.

Targeting A2 adenosine receptors in cancer.

Journal: Immunology and cell biology

Published: December 21, 2016

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

Journal: Cancer research

Published: July 11, 2016

CD73-adenosine reduces immune responses and survival in ovarian cancer patients.

CD73-adenosine reduces immune responses and survival in ovarian cancer patients.

Journal: Oncoimmunology

Published: November 23, 2015

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Journal: Cancer research

Published: December 09, 2014

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.

Journal: Expert opinion on therapeutic targets

Published: May 07, 2014

Anti-CD73 therapy impairs tumor angiogenesis.

Anti-CD73 therapy impairs tumor angiogenesis.

Journal: International journal of cancer

Published: March 26, 2013

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.

Journal: Journal of biomedicine & biotechnology

Published: June 19, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026